drugset / Trial / NCT03695757
Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this prospective pilot clinical study is to evaluate the safety and immunostimulatory effect of intramuscularly administrations of autologous total IgG (autologous total IgG therapy) in healthy subjects and patients with advanced solid tumor (non-small cell lung cancer, stomach cancer, colon cancer, ovarian cancer, breast cancer, pancreatic cancer, biliary cancer, melanoma, renal cell carcinoma etc.). In addition, antitumor effect of intramuscularly administrations of autologous total IgG in patients with advanced solid tumor will be also evaluated.
Timeline
- Start
- 2018-11-06
- Primary completion
- 2021-01-26
- Completion
- 2021-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | autologous total IgG | Protein / enzyme biologic | 50 mg | Intramuscular |
Indications
No indication recorded.